Endocrine Surgery| Volume 285, P229-235, May 2023

Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation

Published:January 27, 2023DOI:



      Secondary hyperparathyroidism (SHP) is common in end-stage renal disease and may progress to persistent post-transplant hyperparathyroidism (PTHP) following renal transplantation (RT). We sought to describe the frequency and determine factors associated with the incidence of PTHP for patients undergoing RT at a single institution that restricts RT for patients with uncontrolled SHP with a parathyroid hormone (PTH) of >800pg/mL at time of initial transplant evaluation.


      We conducted a single-institution retrospective study of adults undergoing index RT from 2012 to 2020 who had a calcium and PTH level within 12 mo prior to RT and at least 6 mo following RT. PTHP was defined as calcium of >10 mg/dL with an elevated PTH > 88pg/mL at six or more months following RT. Univariate analysis and multivariable logistic regression were performed for factors associated with developing PTHP.


      We identified 1110 patients with RT, 65 were excluded for prior RT, 549 did not have a pre-RT and post-RT calcium, and PTH laboratories for inclusion, yielding 496 for analysis. Following RT, 39 patients (7.9%) developed PTHP, compared to those who did not develop PTHP; these patients had significantly higher pre-RT PTH, pre-RT calcium, and frequency of calcimimetic therapy. In multivariable logistic regression factors significantly associated with PTHP were pre-RT calcium of more than 10 mg/dL with an odds ratio (OR) of 3.57 (95% confidence interval [CI] 1.52-8.39, P = 0.003) and pre-RT calcimimetic therapy with an OR 1.30 (95% CI 1.06-2.85, P = 0.041). Compared with patients who had a pre-RT PTH of less than 200 pg/mL, a PTH of 200-399 pg/mL increased risk of PTHP with an OR of 4.52 (95% CI 1.95-21.5, P = 0.048) and a PTH of > 400 pg/mL increased risk of PTHP with an OR of 7.17 (95% CI 1.47-34.9, P = 0.015). In this cohort, 11 patients (28.2%) with PTHP underwent parathyroidectomy (PTx) at a mean of 1.4 y post-RT (standard deviation 0.87).


      For patients required to have a PTH < 800pg/mL for initial transplant candidacy, the subsequent incidence of PTHP is relatively low at 7.9%. Risk factors for PTHP include higher pre-RT calcium and PTH levels and pre-RT calcimimetic therapy. PTx remains underused in the treatment of PTHP. Further study is warranted to determine the optimal PTH cutoff for transplant candidacy and recommendation for PTx in patients requiring calcimimetic therapy for SHP.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Puccini M.
        • Ceccarelli C.
        • Meniconi O.
        • et al.
        Near total parathyroidectomy for the treatment of renal hyperparathyroidism.
        Gland Surg. 2017; 6: 638-643
        • Pihlstrom H.
        • Dahle D.O.
        • Mjoen G.
        • et al.
        Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.
        Transplantation. 2015; 99: 351-359
        • Araujo M.
        • Ramalho J.A.M.
        • Elias R.M.
        • et al.
        Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy.
        Surgery. 2018; 163: 1144-1150
        • Miles C.D.
        • Westphal S.G.
        Electrolyte disorders in kidney transplantation.
        Clin J Am Soc Nephrol. 2020; 15: 412-414
        • Golingan H.
        • Samuels S.K.
        • Camacho P.
        • et al.
        Management of hyperparathyroidism in kidney transplantation candidates: a need for consensus.
        Endocr Pract. 2020; 26: 299-304
        • Lou I.
        • Foley D.
        • Odorico S.K.
        • et al.
        How well does renal transplantation cure hyperparathyroidism?.
        Ann Surg. 2015; 262: 653-659
        • Masaki C.
        • Ogawa S.
        • Shima H.
        • et al.
        Parathyroidectomy for tertiary hyperparathyroidism after second kidney transplantation: a case report.
        CEN case reports. 2021; 10: 208-213
        • Nanmoku K.
        • Shinzato T.
        • Kubo T.
        • Shimizu T.
        • Yagisawa T.
        Prevalence and predictors of early hypercalcemia after kidney transplantation: a nested case-control study within a cohort of 100 patients.
        Clin Exp Nephrol. 2019; 23: 268-274
        • See A.
        • Lim A.E.L.
        • Wong J.
        • et al.
        The effect of parathyroidectomy on patients' symptoms in tertiary hyperparathyroidism.
        Head Neck Aug. 2019; 41: 2748-2755
        • Milas M.
        • Weber C.J.
        Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism.
        Surgery. 2004; 136: 1252-1260
        • Fang L.
        • Wu J.
        • Luo J.
        • et al.
        Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism.
        BMC Nephrol. 2018; 19: 142-018-0934-1
        • Kim Y.J.
        • Kim M.G.
        • Jeon H.J.
        • et al.
        Clinical manifestations of hypercalcemia and hypophosphatemia after kidney transplantation.
        Transplant Proc. 2012; 44: 651-656
        • van der Plas W.
        • Kruijff S.
        • Sidhu S.B.
        • Delbridge L.W.
        • Sywak M.S.
        • Engelsman A.F.
        Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease.
        Surgery. 2021; 169: 275-281
        • Cruzado J.M.
        • Moreno P.
        • Torregrosa J.V.
        • et al.
        A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism.
        J Am Soc Nephrol. 2016; 27: 2487-2494
        • Dewberry L.C.
        • Tata S.
        • Graves S.
        • Weber C.J.
        • Sharma J.
        Predictors of tertiary hyperparathyroidism: who will benefit from parathyroidectomy?.
        Surgery. 2014; 156: 1631-1636
        • Dulfer R.R.
        • Franssen G.J.H.
        • Hesselink D.A.
        • Hoorn E.J.
        • van Eijck C.H.J.
        • van Ginhoven T.M.
        Systematic review of surgical and medical treatment for tertiary hyperparathyroidism.
        Br J Surg. 2017; 104: 804-813
        • Tseng P.Y.
        • Yang W.C.
        • Yang C.Y.
        • Tarng D.C.
        Long-term outcomes of parathyroidectomy in kidney transplant recipients with persistent hyperparathyroidism.
        Kidney Blood Press Res. 2015; 40: 386-394
        • Sutton W.
        • Chen X.
        • Patel P.
        • et al.
        Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.
        Surgery. 2022; 171: 69-76
        • Callender G.G.
        • Malinowski J.
        • Javid M.
        • et al.
        Parathyroidectomy prior to kidney transplant decreases graft failure.
        Surgery. 2017; 161: 44-50
        • Isakov O.
        • Ghinea R.
        • Beckerman P.
        • Mor E.
        • Riella L.V.
        • Hod T.
        Early persistent hyperparathyroidism post-renal transplantation as a predictor of worse graft function and mortality after transplantation.
        Clin Transpl. 2020; 34: e14085
        • Shindo M.
        • Lee J.A.
        • Lubitz C.C.
        • et al.
        The changing landscape of primary, secondary, and tertiary hyperparathyroidism: highlights from the American college of surgeons Panel, “what's new for the surgeon caring for patients with hyperparathyroidism”.
        J Am Coll Surg. 2016; 222: 1240-1250
        • Horl W.H.
        The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes.
        Nephrol Dial Transpl. 2004; 19: V2-V8
        • Kestenbaum B.
        • Andress D.L.
        • Schwartz S.M.
        • et al.
        Survival following parathyroidectomy among United States dialysis patients.
        Kidney Int. 2004; 66: 2010-2016
        • Costa-Hong V.
        • Jorgetti V.
        • Gowdak L.H.
        • Moyses R.M.
        • Krieger E.M.
        • De Lima J.J.
        Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism.
        Surgery. 2007; 142: 699-703
        • Parfrey P.S.
        • Chertow G.M.
        • Block G.A.
        • et al.
        The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
        J Clin Endocrinol Metab. 2013; 98: 4834-4844
        • Chen L.
        • Wang K.
        • Yu S.
        • et al.
        Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
        Ren Fail. 2016; 38: 1050-1058
        • Ivarsson K.M.
        • Akaberi S.
        • Isaksson E.
        • et al.
        The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism.
        Nephrol Dial Transpl. 2015; 30: 2027-2033
        • Narayan R.
        • Perkins R.M.
        • Berbano E.P.
        • et al.
        Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.
        Am J Kidney Dis. 2007; 49: 801-813
        • Schneider R.
        • Kolios G.
        • Koch B.M.
        • Fernandez E.D.
        • Bartsch D.K.
        • Schlosser K.
        An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective.
        Surgery. 2010; 148: 1091-1099
        • Cunningham J.
        • Danese M.
        • Olson K.
        • Klassen P.
        • Chertow G.M.
        Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
        Kidney Int. 2005; 68: 1793-1800
        • Li S.
        • Chen Y.W.
        • Peng Y.
        • Foley R.N.
        • St Peter W.L.
        Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007.
        Am J Kidney Dis. 2011; 57: 602-611
        • Komaba H.
        • Nakanishi S.
        • Fujimori A.
        • et al.
        Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
        Clin J Am Soc Nephrol. 2010; 5: 2305-2314
        • Pitt S.C.
        • Sippel R.S.
        • Chen H.
        Secondary and tertiary hyperparathyroidism, state of the art surgical management.
        Surg Clin North Am. 2009; 89: 1227-1239
        • Thadhani R.
        • Appelbaum E.
        • Pritchett Y.
        • et al.
        Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
        JAMA. 2012; 307: 674-684
        • Dream S.
        • Chen H.
        • Lindeman B.
        Tertiary hyperparathyroidism: why the delay?.
        Ann Surg. 2021; 273: e120-e122
        • Finnerty B.M.
        • Chan T.W.
        • Jones G.
        • et al.
        Parathyroidectomy versus cinacalcet in the management of tertiary hyperparathyroidism: surgery improves renal transplant allograft survival.
        Surgery. 2019; 165: 129-134
        • Kirnap N.G.
        • Kirnap M.
        • Sayin B.
        • Akdur A.
        • Bascil Tutuncu N.
        • Haberal M.
        Risk factors and treatment options for persistent hyperparathyroidism after kidney transplantation.
        Transpl Proc. 2020; 52: 157-161
        • Nakai K.
        • Fujii H.
        • Ishimura T.
        • Fujisawa M.
        • Nishi S.
        Incidence and risk factors of persistent hyperparathyroidism after kidney transplantation.
        Transpl Proc. 2017; 49: 53-56